GB2106111B
(en)
*
|
1981-09-17 |
1985-11-06 |
Takeda Chemical Industries Ltd |
Macbecin derivatives and their production
|
US4578391A
(en)
*
|
1982-01-20 |
1986-03-25 |
Yamanouchi Pharmaceutical Co., Ltd. |
Oily compositions of antitumor drugs
|
JPS59102398A
(ja)
*
|
1982-12-03 |
1984-06-13 |
Takeda Chem Ind Ltd |
新規抗生物質およびその製造法
|
JPH08502488A
(ja)
*
|
1992-10-14 |
1996-03-19 |
アメリカ合衆国 |
前立腺癌および初期神経悪性疾患に対するベンゾキノイドアンサマイシンの殺腫瘍活性
|
US5387584A
(en)
*
|
1993-04-07 |
1995-02-07 |
Pfizer Inc. |
Bicyclic ansamycins
|
CA2166320A1
(fr)
*
|
1993-06-29 |
1995-01-12 |
Randall James Gallaschun |
Derives d'ansamycine, agents antioncogenes et anticancers
|
US5932566A
(en)
*
|
1994-06-16 |
1999-08-03 |
Pfizer Inc. |
Ansamycin derivatives as antioncogene and anticancer agents
|
JPH11504924A
(ja)
*
|
1995-05-02 |
1999-05-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ベンゾキノン類アンサマイシンによる熱耐性の誘導
|
JP4903922B2
(ja)
|
1997-05-14 |
2012-03-28 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
選択された蛋白質を分解する複合化合物
|
US6852496B1
(en)
|
1997-08-12 |
2005-02-08 |
Oregon Health And Science University |
Methods of screening for agents that promote nerve cell growth
|
US6747055B1
(en)
|
1998-07-17 |
2004-06-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-soluble drugs and methods for their production
|
EP1098666B1
(fr)
|
1998-07-17 |
2013-01-16 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Medicaments solubles a l'eau et procedes de preparation de ceux-ci
|
RU2252772C2
(ru)
*
|
1998-12-07 |
2005-05-27 |
Экосмарт Текнолоджиз, Инк. |
Состав для лечения рака и способ применения натуральных растительных масел
|
US6174875B1
(en)
*
|
1999-04-01 |
2001-01-16 |
University Of Pittsburgh |
Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
|
US7238682B1
(en)
|
1999-04-09 |
2007-07-03 |
Sloan-Kettering Institute For Cancer Research |
Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases
|
WO2000061578A1
(fr)
*
|
1999-04-09 |
2000-10-19 |
Sloan-Kettering Institute For Cancer Research |
Procedes et compositions permettant la degradation et/ou l'inhibition des tyrosine kinases appartenant a la famille her
|
US6979574B1
(en)
*
|
1999-08-06 |
2005-12-27 |
Institut Fuer Diagnostik Forshung Gmbh |
Process for detecting binding reactions with use of the measurement of the relaxation of the double refraction of magnetic particles
|
US6887853B2
(en)
*
|
2000-06-29 |
2005-05-03 |
The Trustees Of Boston University |
Use of geldanamycin and related compounds for treatment of fibrogenic disorders
|
US6946456B2
(en)
*
|
2000-07-28 |
2005-09-20 |
Sloan-Kettering Institute For Cancer Research |
Methods for treating cell proliferative disorders and viral infections
|
WO2002036171A1
(fr)
|
2000-11-02 |
2002-05-10 |
Sloan Kettering Institute For Cancer Research |
Methode permettant d'ameliorer l'efficacite d'agents cytotoxiques a l'aide d'inhibiteurs de la hsp 90
|
EP1423080A4
(fr)
*
|
2001-03-01 |
2009-06-03 |
Conforma Therapeutics Corp |
Procede de traitement de troubles proliferatifs d'origine genetique par des inhibiteurs de hsp90
|
DE60213386T2
(de)
*
|
2001-03-30 |
2006-11-23 |
The United States Of America Represented By The Secretary, Department Of Health And Human Services |
Geldanamycinderivate zur krebsbehandlung
|
WO2002094196A2
(fr)
*
|
2001-05-23 |
2002-11-28 |
Sloan Kettering Institute For Cancer Research |
Methode de traitement de cancers associes a des niveaux de her-2 eleves
|
AU2002330998A1
(en)
*
|
2001-08-06 |
2003-02-24 |
Kosan Biosciences, Inc. |
Benzoquinone ansamycins
|
US20090197852A9
(en)
*
|
2001-08-06 |
2009-08-06 |
Johnson Robert G Jr |
Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
|
US6872715B2
(en)
|
2001-08-06 |
2005-03-29 |
Kosan Biosciences, Inc. |
Benzoquinone ansamycins
|
EP1923061A1
(fr)
|
2001-09-24 |
2008-05-21 |
Conforma Therapeutic Corporation |
Procédé pour la préparation de 17-allyl amino geldanamycine (17-AAG) et autres ansamycines
|
DE60225307T2
(de)
*
|
2001-09-24 |
2009-03-19 |
Conforma Therapeutics Corp., San Diego |
Verfahren zur herstellung von 17-allyl-amino-geldanamycin (17-aag) und anderer ansamycine
|
DE60327994D1
(de)
*
|
2002-02-08 |
2009-07-30 |
Conforma Therapeutics Corp |
Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
|
AU2003226285B2
(en)
*
|
2002-04-10 |
2008-01-03 |
Conforma Therapeutics Corporation |
Ansamycin formulations and methods for producing and using same
|
US20060148776A1
(en)
*
|
2003-03-13 |
2006-07-06 |
Conforma Therapeutics Corporation |
Drug formulations having long and medium chain triglycerides
|
US7691838B2
(en)
*
|
2003-05-30 |
2010-04-06 |
Kosan Biosciences Incorporated |
Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
|
US20050020556A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
|
US20050054589A1
(en)
*
|
2003-05-30 |
2005-03-10 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
|
US20050026893A1
(en)
*
|
2003-05-30 |
2005-02-03 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
|
US20050020534A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
|
US20050054625A1
(en)
*
|
2003-05-30 |
2005-03-10 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
|
US20050020557A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
|
US7241754B2
(en)
*
|
2003-06-13 |
2007-07-10 |
Kosan Biosciences, Inc. |
2-Desmethyl ansamycin compounds
|
JP4717003B2
(ja)
|
2003-11-12 |
2011-07-06 |
コーサン バイオサイエンシーズ, インコーポレイテッド |
11−o−メチルゲルダナマイシン化合物
|
US6855705B1
(en)
|
2003-11-12 |
2005-02-15 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
US6875863B1
(en)
|
2003-11-12 |
2005-04-05 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
US6887993B1
(en)
|
2003-11-12 |
2005-05-03 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
JP4869077B2
(ja)
*
|
2003-12-23 |
2012-02-01 |
インフィニティー ディスカヴァリー インコーポレイテッド |
癌治療に使用するベンゾキノン包含アンサマイシン類のアナログ
|
US20060019941A1
(en)
*
|
2003-12-23 |
2006-01-26 |
Infinity Pharmaceuticals, Inc. |
Analogs of benzoquinone-containing ansamycins and methods of use thereof
|
US7491701B2
(en)
*
|
2004-01-27 |
2009-02-17 |
Boys Town National Research Hospital |
Peptides that bind to HSP90 proteins
|
PT1729770E
(pt)
|
2004-03-15 |
2010-02-08 |
Sunesis Pharmaceuticals Inc |
Sns-595 e métodos de utilização do mesmo
|
WO2005105077A1
(fr)
*
|
2004-04-28 |
2005-11-10 |
Massachusetts Eye & Ear Infirmary |
Maladie inflammatoire de l'oeil
|
US20050256097A1
(en)
*
|
2004-05-11 |
2005-11-17 |
Kosan Biosciences, Inc. |
Pharmaceutical solution formulations containing 17-AAG
|
US7259156B2
(en)
*
|
2004-05-20 |
2007-08-21 |
Kosan Biosciences Incorporated |
Geldanamycin compounds and method of use
|
US20080171687A1
(en)
*
|
2004-09-16 |
2008-07-17 |
Abraxis Bioscience, Inc. |
Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
|
US20060067953A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Conforma Therapeutics Corporation |
Oral pharmaceutical formulations and methods for producing and using same
|
CA2598213C
(fr)
*
|
2005-02-18 |
2011-04-19 |
Abraxis Bioscience, Inc. |
Medicaments a hydrophobicite amelioree concus pour etre integres dans des dispositifs medicaux
|
NZ561939A
(en)
|
2005-03-30 |
2011-03-31 |
Conforma Therapeutics Corp |
Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
|
BRPI0608661A2
(pt)
*
|
2005-04-07 |
2010-01-19 |
Conforma Therapeutics Corp |
formulaÇço farmacÊutica, uso de formulaÇço farmacÊutica, e, mÉtodo de preparaÇço de uma formulaÇço farmacÊutica
|
JP2008535927A
(ja)
|
2005-04-12 |
2008-09-04 |
ウィスコンシン アルムニ リサーチ ファンデイション |
ポリマー及びパッセンジャー薬のミセル組成物
|
EP1874296A4
(fr)
*
|
2005-04-29 |
2010-06-30 |
Kosan Biosciences Inc |
Methode pour traiter un myelome multiple au moyen de 17-aag ou de 17-ag ou d'un promedicament de l'un ou de l'autre
|
BRPI0609861A2
(pt)
*
|
2005-04-29 |
2010-05-11 |
Kosan Biosciences Inc |
uso de 17-aag ou 17-ag ou um pró-fármaco de ambos em combinação com um inibidor de proteassoma na preparação de formulações farmacêuticas para tratar mieloma múltiplo
|
US20080032719A1
(en)
*
|
2005-10-01 |
2008-02-07 |
Outland Research, Llc |
Centralized establishment-based tracking and messaging service
|
JP2008543941A
(ja)
*
|
2005-06-21 |
2008-12-04 |
インフィニティ・ディスカバリー・インコーポレイテッド |
アンサマイシン製剤およびその使用方法
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
US20070105874A1
(en)
*
|
2005-09-23 |
2007-05-10 |
Conforma Therapeutics Corporation |
Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
|
US20090042847A1
(en)
*
|
2005-11-23 |
2009-02-12 |
Kosan Biosciences Incorporated |
17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
|
US7648976B2
(en)
*
|
2005-11-23 |
2010-01-19 |
Bristol-Myers Squibb Company |
17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
|
CN101360492A
(zh)
*
|
2005-12-01 |
2009-02-04 |
康福玛医药公司 |
含安莎霉素的组合物
|
US20070167422A1
(en)
*
|
2006-01-18 |
2007-07-19 |
Yu Kwok S |
Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
|
US8658633B2
(en)
*
|
2006-02-16 |
2014-02-25 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for treating conditions of the eye
|
JP2009539994A
(ja)
|
2006-06-12 |
2009-11-19 |
サネシス ファーマシューティカルズ, インコーポレイテッド |
癌の治療のための化合物及び組成物
|
EP3025712A1
(fr)
*
|
2006-08-02 |
2016-06-01 |
Sunesis Pharmaceuticals, Inc. |
Utilisation combinée d'acide (+) -1,4-dihydro-7- [(3s, 4s) -3-methoxy-4- (méthylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylique et de cytarabine (ara-c) pour le traitement de la leucémie
|
PE20081506A1
(es)
*
|
2006-12-12 |
2008-12-09 |
Infinity Discovery Inc |
Formulaciones de ansamicina
|
US7855192B2
(en)
*
|
2007-01-26 |
2010-12-21 |
Kosan Biosciences, Inc. |
Macrolactams by engineered biosynthesis
|
WO2008118601A2
(fr)
*
|
2007-02-27 |
2008-10-02 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Molécules d'anticorps radiomarqué
|
MX2009010667A
(es)
*
|
2007-04-12 |
2010-02-24 |
Joyant Pharmaceuticals Inc |
Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.
|
US20080255080A1
(en)
*
|
2007-04-12 |
2008-10-16 |
Wright James L |
Hydroquinone Ansamycin Formulations
|
WO2009009067A2
(fr)
*
|
2007-07-09 |
2009-01-15 |
Kwon Glen S |
Encapsulation d'agents thérapeutiques dans des micelles
|
US8551964B2
(en)
|
2007-08-23 |
2013-10-08 |
The Regents Of The University Of Colorado |
Hsp90 inhibitors with modified toxicity
|
EP2200653A2
(fr)
|
2007-09-10 |
2010-06-30 |
University of Massachusetts |
Agents antitumoraux ciblant les mitochondries
|
US8518872B2
(en)
*
|
2007-10-22 |
2013-08-27 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
|
US7960420B2
(en)
*
|
2007-12-21 |
2011-06-14 |
Joyant Pharmaceuticals, Inc |
Diazonamide analogs with improved solubility
|
CN101220068B
(zh)
*
|
2008-01-18 |
2012-06-13 |
中国医学科学院医药生物技术研究所 |
一组格尔德霉素衍生物及其制备方法
|
US20090258869A1
(en)
*
|
2008-02-08 |
2009-10-15 |
The Regents Of The University Of California |
Methods and compounds for treatment or prevention of substance-related disorders
|
JP5123429B2
(ja)
*
|
2008-04-29 |
2013-01-23 |
ジョイアント ファーマスーティカルズ、インク. |
インドリン抗癌剤
|
US8153619B2
(en)
*
|
2008-05-22 |
2012-04-10 |
Joyant Pharmaceuticals, Inc. |
Diazonamide analogs
|
EP2348845A4
(fr)
*
|
2008-10-15 |
2013-01-23 |
Infinity Pharmaceuticals Inc |
Compositions d'ansamycine hydroquinone
|
DE102008060549A1
(de)
|
2008-12-04 |
2010-06-10 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
|
WO2011038278A2
(fr)
|
2009-09-25 |
2011-03-31 |
Wisconsin Alumni Research Foundation |
Encapsulation d'agents thérapeutiques dans des micelles
|
WO2011040421A1
(fr)
|
2009-09-29 |
2011-04-07 |
武田薬品工業株式会社 |
Méthode de criblage
|
EP2784076A1
(fr)
|
2009-10-28 |
2014-10-01 |
Joyant Pharmaceuticals, Inc. |
Mimétiques de SMAC dimère
|
CN102603635B
(zh)
*
|
2011-01-21 |
2016-08-03 |
杭州华东医药集团生物工程研究所有限公司 |
格尔德霉素衍生物及其制备方法和用途
|
WO2012145255A2
(fr)
|
2011-04-22 |
2012-10-26 |
Joyant Pharmaceuticals, Inc. |
Analogues de diazonamide
|
US8945627B2
(en)
|
2011-05-05 |
2015-02-03 |
Wisconsin Alumni Research Foundation |
Micelles for the solubilization of gossypol
|
BR112014008400A2
(pt)
|
2011-10-14 |
2017-04-04 |
Novartis Ag |
derivados de 2-carboxamida cicloamino ureia em combinação com os inibidores de hsp90 para o tratamento de doenças proliferativas
|
WO2013074695A1
(fr)
|
2011-11-14 |
2013-05-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Inhibiteurs de hsp90 ayant une toxicité modifiée
|
US10023862B2
(en)
|
2012-01-09 |
2018-07-17 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat beta-catenin-related diseases
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
EP2904119B1
(fr)
|
2012-10-02 |
2020-06-17 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Procédés associés à des états associés à la voie de la détection de l'adn
|
CA2890699A1
(fr)
|
2012-11-07 |
2014-05-15 |
Novartis Ag |
Polytherapie
|
HUE039052T2
(hu)
|
2013-02-19 |
2018-12-28 |
Novartis Ag |
Benzotiofénszármazékok és azok készítményei szelektív ösztrogén receptor lebontóként
|
CN103360312B
(zh)
*
|
2013-07-22 |
2015-06-03 |
山东大学 |
一组格尔德霉素衍生物及其应用
|
CN112472699A
(zh)
|
2013-07-26 |
2021-03-12 |
种族肿瘤学公司 |
改善比生群及衍生物的治疗益处的组合方法
|
WO2015092634A1
(fr)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
Composés et compositions de 1,2,3,4-tétrahydroisoquinoléine en tant qu'antagonistes et agents de dégradation sélectifs des récepteurs des œstrogènes
|
US10093646B2
(en)
|
2014-01-17 |
2018-10-09 |
Novartis Ag |
1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
JP6473457B2
(ja)
|
2014-01-17 |
2019-02-20 |
ノバルティス アーゲー |
Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物
|
CA2976766A1
(fr)
|
2015-03-25 |
2016-09-29 |
Novartis Ag |
Derives n-heterocycliques formyles utilises en tant qu'inhibiteurs de fgfr4
|
US20180153849A1
(en)
|
2015-06-12 |
2018-06-07 |
Wisconsin Alumni Research Foundation |
Multi-drug combinations that act as potent radiosensitizers
|
WO2016203405A1
(fr)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Composés et compositions pour inhiber l'activité de shp2
|
EP3310779B1
(fr)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Composés et compositions pour l'inhibition de l'activité de shp2
|
CN112625028A
(zh)
|
2015-06-19 |
2021-04-09 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
JP6969800B2
(ja)
|
2016-05-04 |
2021-11-24 |
ジェノシアンス ファルマ |
増殖性疾患の治療に使用される置換2,4−ジアミノ−キノリン誘導体
|
EA036446B1
(ru)
|
2016-06-14 |
2020-11-11 |
Новартис Аг |
Соединения и композиции для подавления активности shp2
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
EP3681879A1
(fr)
|
2017-09-11 |
2020-07-22 |
Krouzon Pharmaceuticals, Inc. |
Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
BR112021001148A2
(pt)
|
2018-07-25 |
2021-04-20 |
Advanced Accelerator Applications S.A. |
soluções estáveis de complexo de radionuclídeo concentrado
|
WO2020021465A1
(fr)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Procédé de traitement de tumeurs neuroendocrines
|
US11459340B2
(en)
|
2018-09-18 |
2022-10-04 |
Nikang Therapeutics, Inc. |
Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
|
CN113164776A
(zh)
|
2018-09-25 |
2021-07-23 |
黑钻治疗公司 |
酪氨酸激酶抑制剂组合物、其制备方法和使用方法
|
WO2020064693A1
(fr)
|
2018-09-25 |
2020-04-02 |
Advanced Accelerator Applications (Italy) Srl |
Polythérapie
|
AU2019346550A1
(en)
|
2018-09-25 |
2021-04-22 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
EP4282416A3
(fr)
|
2018-09-29 |
2024-03-06 |
Novartis AG |
Procédé de fabrication d'un composé pour inhiber l'activité de shp2
|
JP2022514315A
(ja)
|
2018-12-20 |
2022-02-10 |
ノバルティス アーゲー |
3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体を含む投与計画及び薬剤組み合わせ
|
CA3124935A1
(fr)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Derives de 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione et leurs utilisations
|
KR20210129672A
(ko)
|
2019-02-15 |
2021-10-28 |
노파르티스 아게 |
치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
|
EP4013749A1
(fr)
|
2019-08-15 |
2022-06-22 |
Black Diamond Therapeutics, Inc. |
Composés d'alcynyle quinazoline
|
CN115052662A
(zh)
|
2019-12-20 |
2022-09-13 |
诺华股份有限公司 |
抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
|
WO2021195206A1
(fr)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Formes polymorphes et utilisations associées
|
JP2023531676A
(ja)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン
|
CN116134027A
(zh)
|
2020-08-03 |
2023-05-16 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
WO2022043557A1
(fr)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Méthode de traitement de cancers exprimant le psma
|
WO2022043556A1
(fr)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Composition pharmaceutique stable
|
EP4204020A1
(fr)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Méthode de traitement de cancers exprimant le psma
|
AU2021409561A1
(en)
|
2020-12-22 |
2023-07-06 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
CA3208313A1
(fr)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Composes d'isoindolinone
|
WO2022170052A1
(fr)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Dérivés de quinazoline, dérivés de pyridopyrimidine, dérivés de pyrimidopyrimidine et leurs utilisations
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
EP4323349A1
(fr)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Composés amide d'isoindolinone utilisés pour traiter des maladies associées à gspt1
|
EP4323350A1
(fr)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Composés d'iso-indolinone
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
WO2023284730A1
(fr)
|
2021-07-14 |
2023-01-19 |
Nikang Therapeutics, Inc. |
Dérivés d'alkylidène en tant qu'inhibiteurs de kras
|
TW202346292A
(zh)
|
2022-03-28 |
2023-12-01 |
美商尼坎醫療公司 |
作為週期蛋白依賴性激酶2抑制劑的磺醯胺基衍生物
|
WO2023214325A1
(fr)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Dérivés de pyrazolopyrimidine et leurs utilisations en tant qu'inhibiteurs de tet2
|
WO2023240024A1
(fr)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Dérivés de sulfamide utilisés en tant qu'inhibiteurs de kinase 2 dépendant de la cycline
|